newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up